A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
Key facts
- Who runs it
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Where
- Annapolis, Bethesda, Fort Bragg, Fort Sam Houston, Portsmouth, San Antonio, San Diego, and Tacoma, United StatesSee the 9 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 15,448 people enrolled
- Started
- 6 Nov 2018
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Egg based influenza vaccines
- Recombinant influenza vaccines
- Cell-culture based influenza vaccines
- Record updated
- 10 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Eligible for care in Department of Defense medical facilities (Defense Enrollment Eligibility Reporting System eligible)
- ≥18 years of age
- At a participating Military Treatment Facility site for the purpose of receiving a seasonal (2018-2019, 2019-2020,2020-2021, 2021-2022) influenza vaccination
- Able to speak English and able to provide informed consent
- Able to receive and respond to texts and/or emails, or a military recruit
Who cannot take part
- Adults intending to receive or who have received the current seasons FluMist Vaccine (LAIV)
- Adults who have already received a flu vaccine within the current season
- Individual who cannot receive a flu vaccine or standard dosing due to another medical condition
- Allergic to gentamicin, polymyxin and/or neomycin
- Individuals who fail to meet the inclusion criteria
Where in United States
- United States Naval AcademyAnnapolis, United States
- USUBethesda, United States
- Walter Reed National Military Medical CenterBethesda, United States
- Womack Army Medical CenterFort Bragg, United States
- Brooke Army Medical CenterFort Sam Houston, United States
- Naval Medical Center - PortsmouthPortsmouth, United States
- Lackland Airforce BaseSan Antonio, United States
- Naval Medical Center -San DiegoSan Diego, United States
- Madigan Army Medical CenterTacoma, United States
About the trial
What the trial wants to find out
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).
The 3 groups in the trial
- Egg based influenza vaccinesExisting treatment, for comparison
Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
- Recombinant influenza vaccinesExisting treatment, for comparison
FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
- Cell-culture based influenza vaccinesExisting treatment, for comparison
Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Participant self-collected versus research coordinator-collected nasal swabs for respiratory viral surveillance following influenza-like illness.Frontiers in public health, 2026
- Randomized Pragmatic Trial of the Comparative Effectiveness of Chicken Egg-Based Inactivated, Mammalian Cell Culture-Based Inactivated, and Recombinant Protein Quadrivalent Seasonal Influenza Vaccines in United States Military Health System Beneficiaries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025
- Record updated
- 10 November 2026